Washington Post Publisher Will Lewis Steps Down After Layoffs 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
U.S. Stock Futures Rise as Markets Brace for Jobs and Inflation Data 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Bausch + Lomb announces a $1.75 billion definitive agreement with Novartis to acquire XIIDRA dry eye treatment, positioning the Ontario-based eye health company as a leader in ocular surface diseases and bolstering its prescription dry eye unit.
With the purchase, Bausch + Lomb will have a considerable opportunity to grow its prescription dry eye unit further. Novartis AG is divesting its XIIDRA dry-eye treatment to the Swiss drugmaker, and the transaction value could go up to $2.5 billion with a $1.75 billion upfront payment.
In any case, Novartis acquired the XIIDRA product from Takeda for $3.4 billion in 2019. Pharmastar reported that under the helm of leadership of chief executive officer Vas Narasimhan, Novartis has been expanding the company by spinning off some of the low-growth business units, such as its Alcon eye care. It has plans to do the same for its Sandoz healthcare company subsidiary.
“This acquisition is a prime example of our strategy in action, as it provides needed scale for the company and transforms our pharmaceuticals business by making us a leader in ocular surface diseases,” Bausch + Lomb’s chairman and CEO, Brent Saunders, said in a press release. “The deal is also expected to accelerate margin expansion through a larger mix of pharmaceutical products in our portfolio, provide strong and immediate earnings accretion and presents a clear path to deleverage, making it financially compelling.”
Marguerite McDonald, M.D., F.A.C.S., OCLI Vision at Oceanside, N.Y., also explained that “Dry eye disease is multi-factorial and can stem from varying root causes, which means differing treatment options are needed. With the acquisition of XIIDRA and the recent approval of MIEBO, Bausch + Lomb enhances its approach to different facets of dry eye and is well positioned to ensure both medicines reach as many patients as possible.”
Photo by: Bausch & Lomb Website
